Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 3.1% at HKD 21.98, with a trading volume of HKD 44.32 million [1] Group 1: Clinical Research - On January 7, Hutchison China MediTech announced that its Syk inhibitor, Sola-pinib, has met the primary endpoint of durable hemoglobin (Hb) response during the 5 to 24 weeks treatment period in the ESLIM-02 study for adult patients with warm antibody autoimmune hemolytic anemia [1] - The ESLIM-02 study is a randomized, double-blind, placebo-controlled clinical trial conducted in China for adult patients with relapsed or refractory primary or secondary warm antibody autoimmune hemolytic anemia who have received at least one standard treatment [1] - The results of the Phase II portion of the ESLIM-02 study were published in The Lancet Haematology in January 2025 [1] Group 2: Future Plans - Hutchison China MediTech plans to submit a new drug application for Sola-pinib to the National Medical Products Administration of China in the first half of 2026 for the treatment of warm antibody autoimmune hemolytic anemia [1] - Complete data from the ESLIM-02 study will be presented at an upcoming academic conference [1]
和黄医药涨超3% 索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血临床研究取积极结果